Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Friday 15 March, 2019

Verseon Corporation

Change of TIDM

RNS Number : 9591S
Verseon Corporation
15 March 2019
 

March 15, 2019

 

Verseon Corporation

 

("Verseon" or the "Company")

 

Change of TIDM

 

FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that effective March 18, 2019, the Company's ticker symbol for the London Stock Exchange will change from 'VSN' to 'VERS'. The Company's ISIN and SEDOL will remain unchanged. 

 

About Verseon

Verseon Corporation is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

- Ends -

For further information, please contact:

 

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000



Arden Partners (NOMAD and Joint Broker)


Ruari McGirr / Ciaran Walsh / Alex Penney

 +44 (0) 20 7614 5900



Cantor Fitzgerald Europe (Joint Broker) 


Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)


Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts


Simon Vane Percy

+44 (0) 1737 821 890

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCSFAEDLFUSEFD

a d v e r t i s e m e n t